Clinical Trial Update: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) [Phase 2]

View source ↗

Summary

Phase 2 trial E-VITA evaluating the combination of eribulin and lapatinib in metastatic breast cancer has been terminated; the update discusses the trial's effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin)
• Tykerb (lapatinib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED